Latest Articles

  • Update on antiobesity pharmacotherapy in adults: Current and emerging options

    Farah Ziyadeh, MD, Sara Saliba, MD, RD, Dania Salih Bacha, MD, Yael Mauer, MD, MPH, Marcio L. Griebeler, MD, DABOM and Bartolome Burguera, MD, PhD
    • Cleveland Clinic Journal of Medicine January 2026, 93 (1) 36-46;
    • DOI: https://doi.org/10.3949/ccjm.93a.24112

    • The authors review antiobesity medications that are currently available or under investigation and discuss how to personalize obesity treatment.

  • Atrial fibrillation in patients with obesity: How can we optimize management?

    Asim Kichloo, MD, Ivan Magallanes Marrufo, MPH and Suhaib Andrabi, MD
    • Cleveland Clinic Journal of Medicine January 2026, 93 (1) 17-20;
    • DOI: https://doi.org/10.3949/ccjm.93a.25032

    • Heart rate and rhythm control therapies often must be adjusted when treating patients with obesity, while other measures can reduce the onset or recurrence of atrial fibrillation.

  • More on the myths and perceived magic of corticosteroids

    Brian F. Mandell, MD, PhD
    • Cleveland Clinic Journal of Medicine January 2026, 93 (1) 6-7;
    • DOI: https://doi.org/10.3949/ccjm.93b.01026

    • It is widely accepted that corticosteroids can partially prevent infusion reactions to intravenous diagnostic and therapeutic agents, but evidence to support this concept is scant.

  • Multicentric reticulohistiocytosis

    Atul Khasnis, MD, MS and Joseph M. Dyer, DO
    • Cleveland Clinic Journal of Medicine January 2026, 93 (1) 9-11;
    • DOI: https://doi.org/10.3949/ccjm.93a.24124

    • A 58-year-old man presented with a 2-month history of joint pain and swelling and a rash.

  • Do corticosteroids prevent reactions to infusions of contrast, monoclonal antibodies, or chemotherapy?

    CME Image
    Dylan T. Timberlake, MD, Sushmitha Boppana, MD and James Fernandez, MD, PhD
    • Cleveland Clinic Journal of Medicine January 2026, 93 (1) 47-53;
    • DOI: https://doi.org/10.3949/ccjm.93a.25026

    • The data and recommendations about corticosteroid pretreatment vary by medication class and the individual medication, necessitating a medication- and patient-specific approach.

  • Should I consider low-dose rivaroxaban (2.5 mg) for my patient with peripheral artery disease?

    Pranay Marlecha, MD, Deborah Hornacek, MD and Pulkit Chaudhury, MD, MS
    • Cleveland Clinic Journal of Medicine December 2025, 92 (12) 742-744;
    • DOI: https://doi.org/10.3949/ccjm.92a.25065

    • For patients with high ischemic risk, rivaroxaban 2.5 mg twice daily with aspirin 81 or 100 mg daily is a proven strategy to reduce major cardiovascular and limb events.

  • LADA: A case for starting insulin therapy at diagnosis

    Byron J. Hoogwerf, MD
    • Cleveland Clinic Journal of Medicine December 2025, 92 (12) 764-766;
    • DOI: https://doi.org/10.3949/ccjm.92a.25084

    • The author discusses factors that support starting insulin therapy at diagnosis in all patients with latent autoimmune diabetes in adults.

  • How should I incorporate emergency contraception counseling into my practice?

    Alexa R. Wilden, MD and Heather M. Wainstein, MD
    • Cleveland Clinic Journal of Medicine December 2025, 92 (12) 738-741;
    • DOI: https://doi.org/10.3949/ccjm.92a.25029

    • Emergency contraception counseling should be provided routinely to women at risk of unintended pregnancy as part of counseling on reproductive goals.

  • How can I select the right thyroid hormone formulation for my patient with hypothyroidism?

    Lea El Hage, MD and Vinni Makin, MBBS, MD
    • Cleveland Clinic Journal of Medicine December 2025, 92 (12) 745-747;
    • DOI: https://doi.org/10.3949/ccjm.92a.25042

    • Knowing the features of the available thyroid hormone formulations can provide a starting point for individualizing therapy for patients who have concerns about product formulations or remain symptomatic despite a normal thyroid-stimulating hormone level.

  • TOC Icon

    Finding the cause of severe hypokalemia: A 4-step approach

    Enmanuel A. Leiva-Murillo, MD, Erwin Bechtold-Javier, MD, Pol Candela-Parrilla, MD and Ana Matas-García, MD, PhD
    • Cleveland Clinic Journal of Medicine December 2025, 92 (12) 748-756;
    • DOI: https://doi.org/10.3949/ccjm.92a.25055

    • This case illustrates the approach to a group of conditions associated with hypokalemia that usually pose a diagnostic challenge.

Previous
Next